{"title":"每日低剂量卡铂治疗老年不可切除非小细胞肺癌患者CCRT后Durvalumab巩固的实际结果","authors":"Keijiro Yamauchi, Riiko Komuta, Hidetaka Tanabe, Masashi Yokoyama, S O Takata, Takafumi Yanase, Yuki Hosono, Shingo Satoh, Naoko Morishita, Hidekazu Suzuki","doi":"10.21873/anticanres.17425","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The clinical benefits of durvalumab consolidation therapy following concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin in elderly patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) remain unclear.</p><p><strong>Patients and methods: </strong>This was a single-institution retrospective cohort study. We analyzed the medical records of consecutive patients diagnosed with NSCLC who received CCRT with daily low-dose carboplatin from April 2014 to March 2021. Outcomes were compared between the overall group and two subgroups: those who received durvalumab consolidation therapy (CCRT-durvalumab group) and those who did not (CCRT-alone group). The primary endpoints were progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>A total of 38 patients (median age: 76 years) were enrolled in this study. The median PFS was 9.9 months in the overall group, 11.7 months in the CCRT-durvalumab group, and 10.2 months in the CCRT-alone group. The median OS was 39.4 months in the overall group, 32.0 months in the CCRT-durvalumab group, and 39.4 months in the CCRT-alone group. There were no significant differences between the two subgroups in terms of PFS [hazard ratio (HR)=0.88, p=0.97] or OS (HR=1.21, p=0.70).</p><p><strong>Conclusion: </strong>In real-world settings, durvalumab consolidation therapy following CCRT with daily low-dose carboplatin does not appear to provide clinical benefits in terms of PFS or OS for elderly patients with unresectable, locally advanced NSCLC.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"369-378"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin.\",\"authors\":\"Keijiro Yamauchi, Riiko Komuta, Hidetaka Tanabe, Masashi Yokoyama, S O Takata, Takafumi Yanase, Yuki Hosono, Shingo Satoh, Naoko Morishita, Hidekazu Suzuki\",\"doi\":\"10.21873/anticanres.17425\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>The clinical benefits of durvalumab consolidation therapy following concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin in elderly patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) remain unclear.</p><p><strong>Patients and methods: </strong>This was a single-institution retrospective cohort study. We analyzed the medical records of consecutive patients diagnosed with NSCLC who received CCRT with daily low-dose carboplatin from April 2014 to March 2021. Outcomes were compared between the overall group and two subgroups: those who received durvalumab consolidation therapy (CCRT-durvalumab group) and those who did not (CCRT-alone group). The primary endpoints were progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>A total of 38 patients (median age: 76 years) were enrolled in this study. The median PFS was 9.9 months in the overall group, 11.7 months in the CCRT-durvalumab group, and 10.2 months in the CCRT-alone group. The median OS was 39.4 months in the overall group, 32.0 months in the CCRT-durvalumab group, and 39.4 months in the CCRT-alone group. There were no significant differences between the two subgroups in terms of PFS [hazard ratio (HR)=0.88, p=0.97] or OS (HR=1.21, p=0.70).</p><p><strong>Conclusion: </strong>In real-world settings, durvalumab consolidation therapy following CCRT with daily low-dose carboplatin does not appear to provide clinical benefits in terms of PFS or OS for elderly patients with unresectable, locally advanced NSCLC.</p>\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 1\",\"pages\":\"369-378\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17425\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17425","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin.
Background/aim: The clinical benefits of durvalumab consolidation therapy following concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin in elderly patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) remain unclear.
Patients and methods: This was a single-institution retrospective cohort study. We analyzed the medical records of consecutive patients diagnosed with NSCLC who received CCRT with daily low-dose carboplatin from April 2014 to March 2021. Outcomes were compared between the overall group and two subgroups: those who received durvalumab consolidation therapy (CCRT-durvalumab group) and those who did not (CCRT-alone group). The primary endpoints were progression-free survival (PFS) and overall survival (OS).
Results: A total of 38 patients (median age: 76 years) were enrolled in this study. The median PFS was 9.9 months in the overall group, 11.7 months in the CCRT-durvalumab group, and 10.2 months in the CCRT-alone group. The median OS was 39.4 months in the overall group, 32.0 months in the CCRT-durvalumab group, and 39.4 months in the CCRT-alone group. There were no significant differences between the two subgroups in terms of PFS [hazard ratio (HR)=0.88, p=0.97] or OS (HR=1.21, p=0.70).
Conclusion: In real-world settings, durvalumab consolidation therapy following CCRT with daily low-dose carboplatin does not appear to provide clinical benefits in terms of PFS or OS for elderly patients with unresectable, locally advanced NSCLC.
期刊介绍：
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
